Harnessing the power of Artificial Intelligence to unlock further potential of known drugs for orphan diseases

We leverage the power of Artificial Intelligence to repurpose drugs for orphan diseases

We are a team of talented scientists with a passion for innovation

Learn about us

STANDARD DRUG DISCOVERY AND DEVELOPMENT

WE CAN REDUCE THOSE NUMBERS TO

OUR APPROACH

PROPRIETARY PIPELINE

PARTNERSHIP

OUR PERFORMANCE INDICATORS

WE COOPERATE WITH

SOM BIOTECH IN THE MEDIA

LATEST NEWS

SOM Biotech announces the database lock of its Phase2b study with SOM3355 in Huntington’s chorea patients and looks for top-line results in August.

July 25, 2024
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, is pleased to announce the database lock of the Phase 2b study SOMCT03 with SOM3355 for the treatment of chorea in Huntington’s Disease. Press Release

SOM Biotech lecture on drug repurposing in Rare Diseases

July 11, 2024
The Continuous Education Institute of the University of Barcelona (IL3) has invited Dr. Insa to lecture on drug repurposing in rare diseases. The event took place on July 10th in the summer university course titled “Rare diseases. From diagnostics to treatment” Course "Enfermedades raras. Del diagnóstico a la terapia" (ub.edu)

The Brazilian Journal of Implantology and Health Sciences cites SOM3355 as a promising therapy for chorea in Huntington’s disease.

June 19, 2024
The current issue of The Brazilian Journal of Implantology and Health Sciences (Volume 6, Issue 6 (2024), Page 1040-105) cites SOM3355 as a promising therapy for chorea in Huntington’s disease.

SOM Biotech appoints George G. Montgomery as Strategic Corporate Advisor

May 28, 2024
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, has appointed George G. Montgomery as Strategic Corporate Advisor to the Board.

SOM Biotech announces the completion of recruitment in the Phase IIb study of the treatment of chorea in Huntington’s disease patients with SOM3355

April 10, 2024
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed.

SOM Biotech announces the election of Silvia Panigone as Executive Chair

March 27, 2024
Barcelona, Spain, March 26th, 2024. SOM Biotech (SOM), a clinical-stage drug discovery and development company based on a unique and proprietary Artificial Intelligent (AI) platform, appoints Silvia Panigone PhD, MBA as Executive Chair of the Board of SOM.